Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - Focus on amelioration of metabolic profile and tissue cytoprotective properties

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Mega, Cristina ^a,b   Vala, Helena ^b   Rodrigues Santos, Paulo ^c,d   Oliveira, Jorge ^b   Teixeira, Frederico ^a   Fernandes, Rosa ^a   Reis, Flávio ^a   De Lemos, Edite Teixeira ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cytoprotective properties; Endocrine and exocrine pancreas lesions; Sitagliptin; Type 2 diabetes; ZDF rat

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SITAGLIPTIN; TRIACYLGLYCEROL; TRIBBLES HOMOLOG 3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER DIABETIC FATTY RAT;

EID: 84901687531     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-42     Document Type: Article

References (69)

1. Diabetes Fact sheet N°312. World Health Organization, Updated March 2013; http://www.who.int/mediacentre/factsheets/fs312/en/
2. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization 1999 (WHO/NCD/NCS/99.2). http://www.staff.ncl. ac.uk/philip.home/who-dmg.pdf
3. Type 2 diabetes: principles of pathogenesis and therapy. Stumvoll M, Goldstein BJ, van Haeften TW, Lancet 2005 365 1333 1346 10.1016/S0140-6736(05) 61032-X 15823385
4. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ, Diabet Med 2007 33 231 244 (Pubitemid 47440080)
5. The beta-cell in human type 2 diabetes. Marchetti P, Lupi R, Del Guerra S, Bugliani M, Marselli L, Boggi U, Adv Exp Med Biol 2010 654 501 514 10.1007/978-90-481-3271-3-22 20217512
6. The Importance of the b-cell in the pathogenesis of type 2 diabetes mellitus. Kahn SE, Am J Med 2000 108 2S 8S 10764844
7. Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Poitout V, Robertson RP, Minireview, Endocrinology 2002 143 2 339 342 11796484 (Pubitemid 34107184)
8. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Del Prato S, Diabet Med 2009 26 12 1185 1192 10.1111/j.1464-5491.2009.02847.x 20002468
9. The [pre-] history of the incretin concept. Creutzfeldt W, Regul Pept 2005 128 2 87 91 10.1016/j.regpep.2004.08.004 15780427 (Pubitemid 40380908)
10. New interpretation of oral glucose tolerance. McIntyre N, Holdsworth CD, Turner DS, Lancet 1964 2 7349 20 21
11. The entero-insular axis: implications for human metabolism. Ranganath LR, Clin Chem Lab Med 2008 46 1 43 56 18020966
12. The incretin concept today. Creutzfeldt W, Diabetologia 1979 16 2 75 85 10.1007/BF01225454 32119 (Pubitemid 9231263)
13. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and healthy subjects. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ, Diabetes 1995 44 9 1126 1131 10.2337/diab.44.9.1126 7657039
14. Incretins: pathophysiological and therapeutic implications of glucosedependent insulinotropic polypeptide and glucagon-like peptide-1. Ranganath LR, J Clin Pathol 2008 61 4 401 409 10.1136/jcp.2006.043232 18375745 (Pubitemid 351518219)
15. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Gallwitz B, Rev Diabet Stud 2005 2 2 61 69 10.1900/RDS.2005.2.61 17491680
16. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Holst JJ, Gromada J, Am J Physiol Endocrinol Metab 2004 287 2 199 E206 10.1152/ajpendo.00545.2003 15271645 (Pubitemid 38943883)
17. Gastric inhibitory polypeptide and glucagonlike peptide-1 in the pathogenesis of type 2 diabetes. Nauck MA, Baller B, Meier JJ, Diabetes 2004 53 3 190 S196
18. Hyperglycemia-induced production of acute phase reactants in adipose tissue. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE, J Biol Chem 2001 276 42077 42083 10.1074/jbc.M107101200 11546817 (Pubitemid 37371113)
19. The role of TNF-and TNF receptors in obesity and insulin resistance. Hotamisligil GS, J Intern Med 1999 245 621 625 10.1046/j.1365-2796.1999.00490.x 10395191 (Pubitemid 29278870)
20. The interleukin-6 and noradrenaline mediated inflammation-stress feedback mechanism is dysregulated in metabolic syndrome: effect of exercise. Martín-Cordero L, García JJ, Hinchado MD, Ortega E, Cardiovasc Diabetol 2011 20 10 42
21. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler PC, Diabetes 2007 56 2016 2027 10.2337/db07-0197 17475933 (Pubitemid 47201819)
22. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin AV, Biden TJ, Diabetologia 2007 50 752 763 10.1007/s00125-006-0590-z 17268797 (Pubitemid 46355827)
23. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Knøp FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T, Diabetes 2007 56 1951 1959 10.2337/db07-0100 17513701 (Pubitemid 47195814)
24. A new class of oral antidiabetic agents. Seshadri KG, Kirubha MHB, Indian J Pharm Sci 2009 71 608 614 10.4103/0250-474X.59541 20376212
25. The incretin system and its role in type 2 diabetes mellitus. Holst JJ, Vilsbøll T, Deacon CF, Mol Cell Endocrinol 2009 297 127 136 10.1016/j.mce.2008.08.012 18786605
26. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ, J Clin Endocrinol Metab 2001 86 8 3717 3723 10.1210/jcem.86.8.7750 11502801 (Pubitemid 32755966)
27. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R, Endocrinology 2002 143 4397 4408 10.1210/en.2002-220405 12399437 (Pubitemid 35239574)
28. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ, J Biol Chem 2003 278 471 478 12409292 (Pubitemid 36043598)
29. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F, Mediators Inflamm 2010 2010 592760 20652060
30. Diabetic nephropathy amelioration by a lowdose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F, Exp Diabetes Res 2011 2011 162092 22203828
31. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Teixeira de Lemos E, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Correia da Silva G, Teixeira N, Silva AS, Carvalho L, Teixeira F, Nutrition 2009 25 3 330 339 10.1016/j.nut.2008.08.014 19062255
32. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Detre S, Saccani Jotti G, Dowsett M, J Clin Pathol 1995 48 876 878 10.1136/jcp.48.9.876 7490328
33. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F, Genome Biol 2002 3 ESEARCH0034 12184808
34. Analysis of relative gene expression data using real-time quantitative PCR and the 2- ÄÄCT method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
35. A radical explanation for glucose-induced beta cell dysfunction. Brownlee M, J Clin Invest 2003 112 1788 1790 10.1172/JCI200320501 14679173 (Pubitemid 38063700)
36. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. Robertson RP, J Biol Chem 2004 279 42351 42354 10.1074/jbc.R400019200 15258147 (Pubitemid 39372114)
37. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Aleksey V, Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC, Diabetes 2009 58 7 1604 1615 10.2337/db09-0058 19403868
38. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for β cell survival in mice. Maida A, Hansotia T, Longuet C, Seino T, Drucker DJ, Gastroenterology 2009 137 2146 2157 10.1053/j.gastro.2009.09.004 19766644
39. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. Yeom JA, Kim ES, Park HS, Ham DS, Sun C, Kim JW, Cho JH, Yoon KH, BMB Rep 2011 44 11 713 718 10.5483/BMBRep.2011.44.11.713 22118536
40. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ, Clin Sci 2011 120 73 80 10.1042/CS20100372 20795946
41. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM, Diabetologia 2010 53 1 153 159 10.1007/s00125-009-1515-4 19756486
42. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB, Diabetes 2006 55 6 1695 1704 10.2337/db05-1602 16731832 (Pubitemid 44324122)
43. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Gonçalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, Reis F, Ambrósio AF, Fernandes R, Diabetes Obes Metab 2012 14 5 454 463 10.1111/j.1463-1326.2011.01548.x 22151893
44. Incretin-Based Therapies: Viewpoints on the way to consensus. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S, Diabetes Care 2009 32 2 223 S231 19875556
45. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, Lee J, Han JS, Na KY, BMC Nephrol 2013 14 98 10.1186/1471-2369-14-98 23621921
46. Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research. Hocher B, Reichetzeder C, Alter ML, Kidney Blood Press Res 2012 36 65 84 10.1159/000339028 22947920
47. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A, Diabetes Care 2004 27 12 2874 2880 10.2337/diacare.27.12.2874 15562200 (Pubitemid 39565052)
48. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Green BD, Flatt PR, Bailey CJ, Diab Vasc Dis Res 2006 3 3 159 165 10.3132/dvdr.2006.024 17160910 (Pubitemid 44902481)
49. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Darnell D, Davis T, GilFillan C, Karrasch J, Lowy A, Bantwal G, Basavanagowdappa H, Chandalia H, Kumar H, Modi K, Paturi V, Seshaiah V, Sethi B, Shah S, Yajnik C, De Mattia G, Ghirlanda G, Hussein Z, Natkunam SK, Ramanathan GR, Sarvar MM, Tan HS, Benatar J, Leikis R, Scott R, Arciszewska M, Babol I, Gabryel A, Krzyczkowska-Bokwa E, Kula M, et al. Diabetes Obes Metab 2008 10 10 959 969 10.1111/j.1463-1326.2007.00839.x 18201203
50. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Deacon CF, Holst JJ, Biochem Biophys Res Commun 2002 294 1 4 10.1016/S0006-291X(02)00359-5 12054731 (Pubitemid 34687205)
51. Extra-pancreatic effects of incretin-based therapies. Gallwitz B, 2014 [Epub ahead of print]
52. Role of IL-1beta in type 2 diabetes. Dinarello CA, Donath MY, Mandrup-Poulsen T, Curr Opin Endocrinol Diabetes Obes 2010 17 4 314 321 20588114
53. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Maedler K, Dharmadhikari G, Schumann DM, Størling J, Handb Exp Pharmacol 2011 203 257 278 10.1007/978-3-642-17214-4-11 21484575
54. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Lee TI, Kao YH, Chen YC, Huang JH, Hsu MI, Chen YJ, Int J Cardiol 2013 168 6 5390 5395 10.1016/j.ijcard.2013.08.051 24012160
55. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A, Metabolism 2013 62 3 347 351 10.1016/j.metabol.2012.09.004 23062489
56. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P, Intern Med 2013 52 19 2179 2187 10.2169/internalmedicine.52.8175 24088749
57. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Duvillié B, Currie C, Chrones T, Bucchini D, Jami J, Joshi RL, Hill DJ, Endocrinology 2002 143 4 1530 1537 11897712 (Pubitemid 34274384)
58. Islet Microvasculature in Islet Hyperplasia and Failure in a Model of Type 2 Diabetes. Li X, Zhang L, Meshinchi S, Dias-Leme C, Raffin D, Johnson JD, Treutelaar MK, Burant CF, Diabetes 2006 55 11 2965 2973 10.2337/db06-0733 17065332 (Pubitemid 44929429)
59. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, Kaku K, Diabetologia 2011 54 5 1098 1108 10.1007/s00125-011-2069-9 21340625
60. Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, Hashiramoto M, Kaku K, Diabetes Obes Metab 2013 15 2 153 163 10.1111/dom.12005 22950702
61. The TRIB3 Q84R Polymorphism and Risk of Early-Onset Type 2 Diabetes. Prudente S, Scarpelli D, Chandalia M, Zhang YY, Morini E, Del Guerra S, Perticone F, Li R, Powers C, Andreozzi F, Marchetti P, Dallapiccola B, Abate N, Doria A, Sesti G, Trischitta V, J Clin Endocrinol Metab 2009 94 1 190 196 10.1210/jc.2008-1365 18984671
62. Tribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetes. Beguinot F, Diabetologia 2010 53 1831 1834 10.1007/s00125-010-1824-7 20567803
63. The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases. Prudente S, Sesti G, Pandolfi A, Andreozzi F, Consoli A, Trischitta V, Endocr Rev 2012 33 4 526 546 10.1210/er.2011-1042 22577090
64. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Liu J, Wu X, Franklin JL, Messina JL, Hill HS, Moellering DR, Walton RG, Martin M, Garvey WT, Am J Physiol Endocrinol Metab 2010 298 565 E576 10.1152/ajpendo.00467.2009 19996382
65. Overexpression of TRB3 gene in adipose tissue of rats with high fructose-induced metabolic syndrome. Bi XP, Tan HW, Xing SS, Wang ZH, Tang MX, Zhang Y, Zhang W, Endocr J 2008 55 747 752 10.1507/endocrj.K08E-049 18497449
66. Signal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver disease. Wang YG, Shi M, Wang T, Shi T, Wei J, Wang N, Chen XM, World J Gastroenterol 2009 15 19 2329 2335 10.3748/wjg.15.2329 19452573
67. The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Prudente S, Hribal ML, Flex E, Turchi F, Morini E, De Cosmo S, Bacci S, Tassi V, Cardellini M, Lauro R, Sesti G, Dallapiccola B, Trischitta V, Diabetes 2005 54 2807 2811 10.2337/diabetes.54.9.2807 16123373 (Pubitemid 41233606)
68. TRIB3 functional Q84R polymorphism is a risk factor for metabolic syndrome and carotid atherosclerosis. Gong HP, Wang ZH, Jiang H, Fang NN, Li JS, Shang YY, Zhang Y, Zhong M, Zhang W, Diabetes Care 2009 32 1311 1313 10.2337/dc09-0061 19389818
69. Control of adipose tissue inflammation through TRB. Ostertag A, Jones A, Rose AJ, Liebert M, Kleinsorg S, Reimann A, Vegiopoulos A, Berriel Diaz M, Strzoda D, Yamamoto M, Satoh T, Akira S, Herzig S, Diabetes 2010 59 1991 2000 10.2337/db09-1537 20522600